DMK
RLMD icon

David M. Knott’s Relmada Therapeutics RLMD Stock Holding History

David M. Knott’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$157K Hold
6,000
– – 0.06% 107
2021
Q2 		$192K Buy
6,000
+3,000
+100% +$104K 0.07% 99
2021
Q1 		$106K Hold
3,000
– – 0.05% 103
2020
Q4 		$96K Hold
3,000
– – 0.04% 85
2020
Q3 		$113K Hold
3,000
– – 0.07% 72
2020
Q2 		$134K Buy
+3,000
New +$127K 0.07% 67

Other funds holding RLMD

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.21B AUM 28.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

David M. Knott's RLMD Position: Q3 2021 in Review

David M. Knott held its Relmada Therapeutics (RLMD) position steady in Q3 2021 at 6,000 shares worth $157K. The position accounts for 0.06% of the portfolio, ranked #107.

David M. Knott first reported a position in RLMD in Q2 2020 and has held it in 6 quarters since. The position peaked at $192K in Q2 2021. 87 funds tracked by Wall St. Rank hold RLMD as of Q3 2021.

  • David M. Knott held 6,000 shares of Relmada Therapeutics worth $157K as of Q3 2021.
  • David M. Knott left its Relmada Therapeutics share count unchanged in Q3 2021.
  • Relmada Therapeutics made up 0.06% of David M. Knott's portfolio in Q3 2021, its #107 holding.
  • David M. Knott first reported a position in Relmada Therapeutics in Q2 2020 and has held it in 6 quarters since.
  • David M. Knott's Relmada Therapeutics position peaked at $192K in Q2 2021.
  • 87 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q3 2021.

Based on David M. Knott's 13F filing for Q3 2021, filed 12 Nov 2021.